ES2160927T3 - PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INTERFERED NATURAL HUMAN ALPHA. - Google Patents

PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INTERFERED NATURAL HUMAN ALPHA.

Info

Publication number
ES2160927T3
ES2160927T3 ES97905395T ES97905395T ES2160927T3 ES 2160927 T3 ES2160927 T3 ES 2160927T3 ES 97905395 T ES97905395 T ES 97905395T ES 97905395 T ES97905395 T ES 97905395T ES 2160927 T3 ES2160927 T3 ES 2160927T3
Authority
ES
Spain
Prior art keywords
natural human
human alpha
interfered
pharmaceutical compositions
neoplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905395T
Other languages
Spanish (es)
Inventor
Giulio Tarro
Renzo Brozzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unihart Corp
Original Assignee
Unihart Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT96RM000136 external-priority patent/IT1283945B1/en
Priority claimed from IT96RM000427 external-priority patent/IT1284852B1/en
Application filed by Unihart Corp filed Critical Unihart Corp
Application granted granted Critical
Publication of ES2160927T3 publication Critical patent/ES2160927T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of natural human alpha-interferon for the preparation of a medicament in liquid form to be administered through peroral route at dosages comprised between 100 UI and 500 UI/day, for therapy of viral infections, in particular viral hepatitis, neoplasia and immune diseases in humans and animals.
ES97905395T 1996-02-28 1997-02-27 PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INTERFERED NATURAL HUMAN ALPHA. Expired - Lifetime ES2160927T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96RM000136 IT1283945B1 (en) 1996-02-28 1996-02-28 Use of natural human alpha-interferon - in preparation of liquid medicaments for peroral administration for treating viral infections, neoplasia and immune diseases
IT96RM000427 IT1284852B1 (en) 1996-06-14 1996-06-14 Use of natural human alpha-interferon - in preparation of liquid medicaments for peroral administration for treating viral infections, neoplasia and immune diseases

Publications (1)

Publication Number Publication Date
ES2160927T3 true ES2160927T3 (en) 2001-11-16

Family

ID=26332096

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97905395T Expired - Lifetime ES2160927T3 (en) 1996-02-28 1997-02-27 PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INTERFERED NATURAL HUMAN ALPHA.

Country Status (14)

Country Link
US (1) US6884411B1 (en)
EP (1) EP0886527B1 (en)
JP (1) JP2000506839A (en)
KR (1) KR100394382B1 (en)
AT (1) ATE205397T1 (en)
AU (1) AU722987B2 (en)
BR (1) BR9707772A (en)
DE (1) DE69706657T2 (en)
DK (1) DK0886527T3 (en)
EA (1) EA001147B1 (en)
ES (1) ES2160927T3 (en)
GE (1) GEP20012489B (en)
PT (1) PT886527E (en)
WO (1) WO1997031649A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032711A1 (en) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Use of insulin-like growth factor type i and interferon alpha in the treatment of a chronic hepatic disease, kit and compositions comprising same
ES2303492A1 (en) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Use of insulin-like growth factor type i and interferon alpha in the treatment of a chronic hepatic disease, kit and compositions comprising same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
ITMI20030826A1 (en) * 2003-04-18 2004-10-19 Unihart Corp PHARMACEUTICAL COMPOSITION CONTAINING INTERFERONE FOR THE
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
TW224053B (en) * 1991-09-13 1994-05-21 Paul B Chretien
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032711A1 (en) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Use of insulin-like growth factor type i and interferon alpha in the treatment of a chronic hepatic disease, kit and compositions comprising same
ES2303492A1 (en) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Use of insulin-like growth factor type i and interferon alpha in the treatment of a chronic hepatic disease, kit and compositions comprising same

Also Published As

Publication number Publication date
DE69706657D1 (en) 2001-10-18
KR19990082559A (en) 1999-11-25
ATE205397T1 (en) 2001-09-15
AU2229997A (en) 1997-09-16
BR9707772A (en) 2000-01-04
PT886527E (en) 2001-12-28
EA001147B1 (en) 2000-10-30
JP2000506839A (en) 2000-06-06
AU722987B2 (en) 2000-08-17
WO1997031649A1 (en) 1997-09-04
US6884411B1 (en) 2005-04-26
EP0886527B1 (en) 2001-09-12
EP0886527A1 (en) 1998-12-30
GEP20012489B (en) 2001-07-25
EA199800770A1 (en) 1999-02-25
KR100394382B1 (en) 2004-02-05
DE69706657T2 (en) 2002-06-20
DK0886527T3 (en) 2002-03-04

Similar Documents

Publication Publication Date Title
AR012614A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A SUSCEPTIBLE VIRAL INFECTION OF TREATMENT WITH ALPHA INTERFER, A METHOD FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, FOR THE MANUFACTURE OF A MEDICINE
HUP0101293A2 (en) Aspb28-human insulin comprising pharmaceutical composition administered by inhalation and their use
ATE165000T1 (en) DOSAGE FORM FOR DELAYED RELEASE
DK0911033T4 (en) Use of consensus interferon to reduce the side effects of interferon therapy in viral hepatitis
AR019551A1 (en) USE OF RIBAVIRINE IN COMBINATION WITH INTERFERON ALFA FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS NOT AFFECTED TO ANTIVIRAL TREATMENT THAT HAVE INFECTION OF CHRONIC HEPATITIS C
MX171191B (en) PHARMACEUTICAL COMPOSITIONS OF GLIPIZIDE
ATE435294T1 (en) ADMINISTRATION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
GR3025502T3 (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals.
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
RU92016463A (en) APPLICATION OF DERIVATIVES OF TISSTINES FOR THE MANUFACTURE OF MEDICINES WITH IMMUNOMODING EFFECT, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS
AR042262A2 (en) USE OF 8,9-DIHYDROESTRONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ATEROSCLEROSIS
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
DK0502092T3 (en) Oral preparation for the treatment of inflammatory bowel diseases
DE3688841T2 (en) LOW INTERFERON DOSAGE FOR INCREASING VACCINE EFFECTIVENESS.
GB2255093A (en) Hiv-1 core protein fragments
CY1110078T1 (en) INJECTIONS WITH IODIDATED POVIDON FOR WASTE HEALING
DK561089A (en) USE OF LACTAMIMIDES FOR THE PREPARATION OF MEDICINAL PRODUCTS
ES2160927T3 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INTERFERED NATURAL HUMAN ALPHA.
BR0108997A (en) Adjuvant Immune Therapy for HIV
HUP0401593A2 (en) Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
ES2089286T3 (en) NEW 2-AMINO-5-CIANO-1,4-DIHIDROPIRIDINAS, PROCEDURE FOR ITS PREPARATION AND USE IN MEDICINES.
MY112888A (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
DK0427633T3 (en) Use of a polypeptide with gamma interferon activity for the preparation of pharmaceutical preparations intended for the treatment of primitive pleural cancer
ATE348628T1 (en) TREATING HEPATITIS C WITH THYMOSIN, INTERFERON AND RIBAVIRIN

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 886527

Country of ref document: ES